Clinical performance characteristics of the adiana® system for permanent contraception: the first year of commercial use.

In 2009, the Adiana® System for Permanent Contraception was approved by the US Food and Drug Administration and became the second device on the market for hysteroscopic sterilization. This article outlines the basics of the Adiana procedure as it relates to the initial 12-month clinical experience following commercial launch. Safety, efficacy, and practical applications are explored to provide a better understanding of product performance characteristics in the first year of actual clinical use.